With every passing day, new discoveries are made that lend support to the increasing and important role biomarker analysis and tumor profiling play in personalized cancer care. Caris Life Sciences® is actively participating in research to advance the understanding of molecular science, further enabling the delivery of precision medicine.

Comparison of progression-free survival (PFS) on comprehensive multiplatform profiling-guided therapy to PFS on prior therapy-

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy

High-Intermediate Risk Endometrial Cancer: Can Gene Expression Predict Recurrence?

Molecular Profiling for Clinical Decision Making in Advanced Cancer: A Clinical Appraisal

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

Identification of molecular targets in vulvar cancers

Comparative molecular profiling of HPV-induced squamous cell carcinomas

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations

Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade

RNASeq analysis of glioma tumors reveal targetable gene fusions